{"filing":{"accession_number":"0001493152-26-041801","cik":"0001583771","ticker":"CTRVP","company_name":"Hepion Pharmaceuticals, Inc.","form":"8-K","filing_date":"2026-09-08","report_date":"2026-09-03","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1583771/000149315226041801/form8-k.htm"},"events":[{"id":32089,"run_id":29478,"accession_number":"0001493152-26-041801","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Hepion Pharmaceuticals issued a $500,000 secured convertible note to Gravitas Capital LP on September 3, 2026, bearing 8% interest and maturing September 3, 2027, convertible into common stock at $0.04 per share and secured by all company assets.","company_name":"Hepion Pharmaceuticals, Inc.","ticker":"CTRVP","filing_date":"2026-09-08","form":"8-K","submitted_at":null,"items":[{"id":35172,"accession_number":"0001493152-26-041801","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Hepion Pharmaceuticals issued a $500,000 secured convertible note to Gravitas Capital LP on September 3, 2026, bearing 8% interest and maturing September 3, 2027. The note is convertible into common stock at $0.04 per share and is secured by all company assets. This constitutes creation of a direct financial obligation under Item 2.03, and the convertible structure with warrant attachment is a material debt issuance typical of small-cap financing activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:25:56.459623+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35173,"accession_number":"0001493152-26-041801","item_number":"3.02","item_title":"Unregistered Sale of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities by Hepion Pharmaceuticals. The exhibits reference a convertible note, warrant, and convertible note purchase agreement, indicating a private placement of convertible debt with equity warrants—a classic dilutive issuance structure. The incorporation of Item 1.01 (which typically describes the transaction terms) reinforces this as a material capital-raising event involving equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:25:56.459623+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35172,"accession_number":"0001493152-26-041801","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Hepion Pharmaceuticals issued a $500,000 secured convertible note to Gravitas Capital LP on September 3, 2026, bearing 8% interest and maturing September 3, 2027. The note is convertible into common stock at $0.04 per share and is secured by all company assets. This constitutes creation of a direct financial obligation under Item 2.03, and the convertible structure with warrant attachment is a material debt issuance typical of small-cap financing activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:25:56.459623+00:00","company_name":"Hepion Pharmaceuticals, Inc.","ticker":"CTRVP","filing_date":"2026-09-08"},{"id":35173,"accession_number":"0001493152-26-041801","item_number":"3.02","item_title":"Unregistered Sale of Equity Securities.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 3.02 discloses an unregistered sale of equity securities by Hepion Pharmaceuticals. The exhibits reference a convertible note, warrant, and convertible note purchase agreement, indicating a private placement of convertible debt with equity warrants—a classic dilutive issuance structure. The incorporation of Item 1.01 (which typically describes the transaction terms) reinforces this as a material capital-raising event involving equity dilution.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-08T21:25:56.459623+00:00","company_name":"Hepion Pharmaceuticals, Inc.","ticker":"CTRVP","filing_date":"2026-09-08"}]}